



with the proviso that:

(1) R^3 is not –OH (a) when R^1 is –OH or (b) when R^1 and R^2 together form , wherein R^4 is $C_{1\text{-}9}$alkyl or  and


(2) R^3 is not .

[0005a] In one aspect, there is provided a compound of Formula (1000):



(**1000**);

or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, wherein:

R^1 and R^2 together form ;

either (a), or (b), or (c):

(a) R^3 is selected from the group consisting of -X-arylene-Y-NR^aR^b and -X-heteroarylene-Y-NR^aR^b; wherein X is -O-; wherein Y is absent; wherein the arylene or heteroarylene is optionally substituted with halogen, deuterium, hydroxyl, or methoxyl; and

R^4 is selected from the group consisting of alkyl, aryl, alkylaryl, arylalkyl, heteroaryl, -alkylene-NR^aR^b, -X-arylene-Y-NR^aR^b, -X-heteroarylene-Y-NR^aR^b, and N-containing heterocycloalkyl; wherein X is absent, -NR^a-, -CH_2-, or -O-; wherein Y is absent or -CH_2-;

or

(b) R^3 is selected from the group consisting of -NR^aR^b, -X-arylene-Y-NR^aR^b, and -X-heteroarylene-Y-NR^aR^b; wherein X is -O-; wherein Y is absent; wherein the arylene or heteroarylene is optionally substituted with halogen, deuterium, hydroxyl, or methoxyl; and

R^4 is selected from the group consisting of -alkylene-NR^aR^b, -X-arylene-Y-NR^aR^b, -X-heteroarylene-Y-NR^aR^b, and N-containing heterocycloalkyl; wherein X is absent, -NR^a-, -CH_2-, or -O-; wherein Y is absent or -CH_2-;

or

(c) R^3 is -NR^aR^b;

















R^4 is alkyl;


R^5 is, independently in each instance, -OH, halo, or alkyl; and each R^5 is positioned on any ring atom;


R^a and R^b are, independently in each instance, -H or unsubstituted alkyl; or R^a and R^b cyclize to form cycloheteroalkyl with three to six ring atoms, including one hetero atom, which is the N to which they are attached; and


n is an integer from 0-16.


[0005b] In another aspect, there is provided a compound selected from:

























































and



or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.


[0005c] In another aspect, there is provided a conjugate compound comprising a binding agent conjugated to a compound as defined herein.

[0006] In certain examples, the compounds are protein-drug conjugates, *e.g.*, antibody-drug conjugates, comprising an antigen-binding protein, *e.g.*, antibody and a compound of Formula (**A**).

[0006a] In another aspect, there is provided a conjugate compound comprising a binding agent conjugated to a compound as defined herein and a cyclodextrin (**CD**).

[0007] In certain examples, the compounds are protein-drug conjugates, *e.g.*, antibody-drug conjugates, comprising an antigen-binding protein, *e.g.*, antibody, a compound of Formula (**A**), and a cyclodextrin moiety.

[0007a] In another aspect, there is provided a conjugate compound comprising a binding agent conjugated to a compound of Formula (**A'**) and a cyclodextrin (**CD**); wherein the compound of Formula (**A'**) is:



(**A'**);

or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof,

wherein:

R^1 and R^2 together form ,

wherein R^4 is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl, wherein the alkyl, aryl, arylalkyl, and N-containing heterocycloalkyl are, independently in each instance, optionally substituted with $-NR^aR^b$;

R^3 is $-NR^aR^b$, -oxyaryl-NR^aR^b, or -Z-A$(R^P)_t$,

R^5 is, independently in each instance, -OH, halo, alkyl, or arylalkyl;

Z is O;

A is aryl or heteroaryl;

R^P is, independently in each instance, halo, optionally substituted alkyl, -OH, or $-NR^aR^b$;

wherein at least one R^P is $-NR^aR^b$;

R^a and R^b are, independently in each instance, -H, unsubstituted alkyl, or optionally substituted aryl;

n is an integer from 0-19; and


t is an integer from 1-3.


[0007b] In another aspect, there is provided use of the compound as defined herein or the conjugate compound as defined herein in the manufacture of a medicament for treating a disease, disorder, or condition associated with glucocorticoid receptor signaling.


[0007c] In another aspect, there is provided an *in vitro* method of delivering a compound as defined herein to a cell comprising contacting said cell with a protein conjugate of said compound, wherein said protein conjugate comprises an antibody or antigen binding fragment thereof that binds a surface antigen of said cell.


[0007d] In another aspect, there is provided a linker-payload compound comprising the compound as defined herein linked to a reactive group, optionally via a linker.


[0007e] In another aspect, there is provided a linker-payload compound selected from the group consisting of:






















































and



.

[0007f] In another aspect, there is provided a pharmaceutical composition comprising a therapeutically effective amount of the compound as defined herein or the conjugate compound as defined herein.

BRIEF DESCRIPTIONS OF THE DRAWINGS

[0008] FIG. 1. shows a sequence for synthesizing the certain steroids described herein.

[0009] FIG. 2. shows a sequence for modifying the primary alcohol position of budesonide.

[0010] FIG. 3. shows a sequence for modifying the primary alcohol position of Flumethasone.

[0011] FIG. 4. shows a sequence for modifying the primary alcohol position of dexamethasone.

[0012] FIG. 5 shows a two–dimensional nuclear Overhauser effect (NOE) magnetic resonance spectrum (hereinafter "2D–NOESY") for compound 7-1*R* in Table 1.


[0013] FIG. 6 shows a 2D–NOESY for compound 7-1*S* in Table 1.

[0014] FIG. 7 shows a 2D–NOESY spectrum for 11-5*R* in Table 1.

[0015] FIG. 8 shows a 2D–NOESY spectrum for compound 11-5*S* in Table 1.

What is claimed is:

1. A compound of Formula (**1000**):



(**1000**);

or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof,

wherein:

R^1 and R^2 together form  ;

either (a), or (b), or (c):

(a) R^3 is selected from the group consisting of -X-arylene-Y-NR^aR^b and -X-heteroarylene-Y-NR^aR^b; wherein X is -O-; wherein Y is absent; wherein the arylene or heteroarylene is optionally substituted with halogen, deuterium, hydroxyl, or methoxyl; and

R^4 is selected from the group consisting of alkyl, aryl, alkylaryl, arylalkyl, heteroaryl, -alkylene-NR^aR^b, -X-arylene-Y-NR^aR^b, -X-heteroarylene-Y-NR^aR^b, and N-containing heterocycloalkyl; wherein X is absent, -NR^a-, -CH_2-, or -O-; wherein Y is absent or -CH_2-;

or

(b) R^3 is selected from the group consisting of -NR^aR^b, -X-arylene-Y-NR^aR^b, and -X-heteroarylene-Y-NR^aR^b; wherein X is -O-; wherein Y is absent; wherein the arylene or heteroarylene is optionally substituted with halogen, deuterium, hydroxyl, or methoxyl; and

R^4 is selected from the group consisting of -alkylene-NR^aR^b, -X-arylene-Y-NR^aR^b, -X-heteroarylene-Y-NR^aR^b, and N-containing heterocycloalkyl; wherein X is absent, -NR^a-, -CH_2-, or -O-; wherein Y is absent or -CH_2-;

or

(c) R^3 is -NR^aR^b;


R^4 is alkyl;

R^5 is, independently in each instance, -OH, halo, or alkyl; and each R^5 is positioned on any ring atom;

R^a and R^b are, independently in each instance, -H or unsubstituted alkyl; or R^a and R^b cyclize to form cycloheteroalkyl with three to six ring atoms, including one hetero atom, which is the N to which they are attached; and

n is an integer from 0-16.


2. The compound of claim 1, wherein the compound of Formula (**1000**) has the structure of Formula (**A[1]**):




(**A[1]**)

wherein R^1-R^3 are as defined above and R^{5A} and R^{5B} are each, independently, halo or a hydrogen atom.

3. The compound of claim 2, wherein R^1 and R^2 together form , wherein R^4 is aryl, arylalkyl, or alkyl, or wherein R^4 is -alkylene-NR^aR^b or -X-arylene-Y-NR^aR^b wherein X is absent or CH_2 and Y is absent.

4. The compound of any of claims 1-3, wherein R^3 is -NR^aR^b or , wherein R^P is halo, t is an integer from 0 to 2, R^a is H, or R^b is H or unsubstituted alkyl.

5. The compound of claim 1 according to Formula (**A[4]**):




(**A[4]**)

wherein R^3 is –NR^aR^b and R^4 is alkyl, wherein R^a and R^b are each, independently, a hydrogen atom or unsubstituted alkyl, or R^a and R^b cyclize to form cycloheteroalkyl with three to six ring atoms, including one hetero atom, which is the N to which they are attached.

6. The compound of claim 5, wherein R^4 is $C_{1\text{-}4}$ alkyl.

7. The compound of claim 5 or 6, wherein R^3 is $-NH_2$, $-NHCH_3$, or $-N(CH_3)_2$.


8. The compound of claim 1 according to Formula (**A^5**):




(**A^5**)

wherein R^4 is alkyl, R^{P1} is halo or a hydrogen atom, and R^{P2} is $-NR^aR^b$, wherein R^a and R^b are each, independently, a hydrogen atom or unsubstituted alkyl.


9. The compound of claim 1 according to Formula (**A^6**):



(**A^6**)

wherein R^3 is  or NR^aR^b, wherein X is O,  is aryl or heteroaryl, R^P is halo, t is an integer from 0-2, R^a and R^b are each, independently, a hydrogen atom or unsubstituted alkyl, and R^4 is alkyl

10. The compound of claim 1 according to Formula **1000**:



1000

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof,

wherein:

R^1 and R^2 together form ,

either (a) or (c):

(a) R^3 is selected from the group consisting of -X-arylene-Y-NR^aR^b and -X-heteroarylene-Y-NR^aR^b; wherein X is -O-; wherein Y is absent; wherein the arylene or heteroarylene is optionally substituted with halogen, deuterium, hydroxyl, or methoxyl; and

R^4 is selected from the group consisting of alkyl, aryl, alkylaryl, arylalkyl, heteroaryl, -alkylene-NR^aR^b, -X-arylene-Y-NR^aR^b, -X-heteroarylene-Y-NR^aR^b, and N-containing heterocycloalkyl; wherein X is absent, -NR^a-, -CH_2-, or -O-; wherein Y is absent or -CH_2-;

or

or


(c) R^3 is -NR^aR^b; and

R^4 is alkyl;


R^5 is, independently in each instance, selected from a substituent in the group consisting of –OH, halo, and alkyl; n is an integer from 0-16; and each R^5 is positioned on any ring atom;

R^a and R^b are, independently in each instance, selected from the group consisting of -H and unsubstituted alkyl; or R^a and R^b cyclize to form cycloheteroalkyl with three to six ring atoms, including one hetero atom, which is the N to which they are attached.


11. The compound of claim 10 according to Formula **1110**, **1120**, **1130**, or **1140**:




1110



1120



1130



1140


or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

12. The compound of claim 11 wherein

R^3 is $-NR^aR^b$; and


R^4 is n-propyl.

13. The compound of claim 12 according to formula **1120**.

14. The compound of claim 11 wherein R^4 is $H_2NCH_2CH_2$- or .







15. The compound of claim 11 wherein


R^3 is -X-arylene-Y-NR^aR^b, or -X-heteroarylene-Y-NR^aR^b; X is -O-; Y is absent; and R^4 is alkyl, aryl, alkylaryl, or arylalkyl.

16. The compound of claim 15 wherein R^3 is $-NH_2$, $-N(H)CH_3$, $-N(CH_3)_2$, or .

17. The compound of claim 15 wherein R^3 is -O-arylene-NR^aR^b or -O-heteroarylene-NR^aR^b; wherein the arylene or heteroarylene is optionally substituted with halogen, deuterium, hydroxyl, or methoxyl.


18. The compound of claim 15 wherein R^3 is -O-phenylene-NR^aR^b or -O-heteroarylene-NR^aR^b; wherein the phenylene or heteroarylene is optionally substituted with halogen or deuterium.


19. The compound of claim 15 wherein R^3 is , , , , , or .


20. The compound of claim 15, wherein R^3 is .


21. The compound of any of claims 15-20, wherein R^4 is n-propyl.


22. A compound selected from:

































and




or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

23. A conjugate compound comprising a binding agent conjugated to a compound of any of claims 1-22.

24. A conjugate compound comprising a binding agent conjugated to a compound of any of claims 1-22 and a cyclodextrin (**CD**).


25. A conjugate compound comprising a binding agent conjugated to a compound of Formula (**A'**) and a cyclodextrin (**CD**); wherein the compound of Formula (**A'**) is:



(**A'**);

or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof,

wherein:

R^1 and R^2 together form ,

wherein R^4 is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl, wherein the alkyl, aryl, arylalkyl, and N-containing heterocycloalkyl are, independently in each instance, optionally substituted with $-NR^aR^b$;

R^3 is $-NR^aR^b$, -oxyaryl-NR^aR^b, or -Z-A$(R^P)_t$,

R^5 is, independently in each instance, -OH, halo, alkyl, or arylalkyl;

Z is O;

A is aryl or heteroaryl;

R^P is, independently in each instance, halo, optionally substituted alkyl, -OH, or $-NR^aR^b$;



wherein at least one R^P is $-NR^aR^b$;





R^a and R^b are, independently in each instance, -H, unsubstituted alkyl, or optionally substituted aryl;

n is an integer from 0-19; and

t is an integer from 1-3.

26. The conjugate compound of claim 24 or 25, wherein **CD** is selected from the group consisting of


, ,


,

,

, and

, wherein ⁄ indicates the bond through which the CD is linked to the binding agent conjugate.

27. The conjugate compound of any one of claims 23 to 28, wherein the binding agent is an antibody or antigen binding fragment thereof.

28. The conjugate compound of claim 23, wherein the binding agent is an antibody or antigen binding fragment thereof

29. The conjugate compound of claim 23, according to Formula **1200**:



1200

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof,

wherein:

R^1 and R^2 together form  ; and

either (a), or (b), or (c):

(a) R^3 is selected from the group consisting of -X-arylene-Y-NR^aR^b or -X-heteroarylene-Y-NR^aR^b; wherein X is -O-; wherein Y is absent; wherein the arylene or heteroarylene is optionally substituted with halogen, deuterium, hydroxyl, or methoxyl; and

R^4 is selected from the group consisting of alkyl, aryl, alkylaryl, arylalkyl, heteroaryl, -alkylene-NR^aR^b, -X-arylene-Y-NR^aR^b, -X-heteroarylene-Y-NR^aR^b, and N-containing heterocycloalkyl; wherein X is absent, -NR^a-, -CH_2-, or -O-; wherein Y is absent or -CH_2-;

or

(b) R^3 is selected from the group consisting of -NR^aR^b, -X-arylene-Y-NR^aR^b, and -X-heteroarylene-Y-NR^aR^b; wherein X is -O-; wherein Y is absent; wherein the arylene or heteroarylene is optionally substituted with halogen, deuterium, hydroxyl, or methoxyl; and

R^4 is selected from the group consisting of -alkylene-NR^aR^b, -X-arylene-Y-NR^aR^b, -X-heteroarylene-Y-NR^aR^b, and N-containing heterocycloalkyl; wherein X is absent, -NR^a-, -CH_2-, or -O-; wherein Y is absent or -CH_2-;

or

(c) R^3 is -NR^aR^b; and

R^4 is alkyl;

R^5 is, independently in each instance, selected from a substituent in the group consisting of –OH, halo, and alkyl; n is an integer from 0-16; and each R^5 is positioned on any ring atom;

R^a and R^b are, independently in each instance, selected from the group consisting of -H and unsubstituted alkyl; or R^a and R^b cyclize to form cycloheteroalkyl with three to six ring atoms, including one hetero atom, which is the N to which they are attached;


BA is a binding agent;

each L is an optional linker;


BA or L is covalently bonded to R^3 or R^4; and

x is an integer from 1 to 30.


30. The conjugate compound of claim 29 according to Formula **1310**, **1320**, **1330**, or **1340**:




1310



1320



1330





1340


or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof;


wherein R^4 is covalently bonded to L or BA.


31. The conjugate compound of claim 23 selected from the group consisting of:











































































or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof;


wherein each L is an optional linker;


each BA is a binding agent; and


each x is an integer from 1 to 30.


32. The conjugate compound of claim 23 selected from the group consisting of:
























































,




,




,





,





,


















































wherein x is an integer from 1 to 30; and n is an integer from 1 to 30;
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

33. Use of the compound of any of claims 1-22 or the conjugate compound of any one of claims 23-32 in the manufacture of a medicament for treating a disease, disorder, or condition associated with glucocorticoid receptor signaling.

34. The use of claim 33, wherein the disease, disorder, or condition, is an inflammatory disease, disorder, or condition.


35. The use of claim 34, wherein a compound of any one of claims 12-14 is to be administered.


36. The use of claim 35, wherein side effects associated with administration of the unconjugated steroid payload of said compound are to be reduced.


37. A *in vitro* method of delivering a compound of claim 1 to a cell comprising contacting said cell with a protein conjugate of said compound, wherein said protein conjugate comprises an antibody or antigen binding fragment thereof that binds a surface antigen of said cell.


38. A linker-payload compound comprising the compound of any of claims 1-22 linked to a reactive group, optionally via a linker.


39. A linker-payload compound selected from the group consisting of:





















































and






.

40. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1-22 or the conjugate compound of any one of claims 23-32.



41. The compound of claim 22, wherein the compound is one of the following:


and

; or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.


42. The compound of claim 41, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

43. The compound of claim 41, wherein the compound is

or

; or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

44. The conjugate compound of claim 29, wherein the binding agent is conjugated to one of the following:



and

; or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

45. The conjugate compound of claim 44, wherein the compound is conjugated to




R- or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

46. The conjugate compound of claim 44, wherein the compound is conjugated to




or




; or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

47. The conjugate compound of claim 31, wherein the conjugate compound is one of the following:





and



.


48. The conjugate compound of claim 32, wherein the compound is






wherein x is an integer from 1 to 30; or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

49. The compound of claim 38, wherein the reactive group is linked to one of the following:




and



.

50. The linker payload compound of claim 39, of the structure:



.

51. The conjugate compound of claim 29, wherein BA is an antibody modified with one or more H_2N-LL-N_3 groups, wherein LL is divalent polyethylene glycol.